Agilent Technologies

About: Agilent Technologies is a company organization based out in Santa Clara, California, United States. It is known for research contribution in the topics: Signal & Mass spectrometry. The organization has 7398 authors who have published 11518 publications receiving 262410 citations. The organization is also known as: Agilent Technologies, Inc..

Lancet device with skin movement control and ballistic preload

Abstract: A device for puncturing the skin of a patient. The device includes a lancet for puncturing the skin and a skin stabilizer associated with the lancet for stabilizing the skin to reduce its freedom of movement when the lancet strikes it. The skin stabilizer has an opening through which the lancet can pass to puncture the skin. The skin stabilizer applies pressure on the skin around the opening. The application of pressure, in additional to reducing the freedom of movement of the skin directly held by the skin stabilizer, also increases the tautness of the skin in the opening prior to the lancet penetrating the skin. The opening is not substantially larger than the size of the lancet.

Method and system for managing data service systems

Abstract: A scheme is described for a data service system having a number of modules. Some of the modules are interdependent. To measure the status of an individual module, the scheme first collects measurements from a number of measurement routes that involve the module. Then the scheme analyzes the interdependencies of the measurements to determine the status of the individual module. The scheme may also determine status of the data service system with a minimal number of measurement routes. This is done by determining (1) all possible measurement routes, (2) determining the dependency between the modules and the measurement routes, and (3) analyzing the dependency to select minimal number of the measurement routes. The scheme can diagnose whether a module is a problematic module or not by analyzing a number of measurements that involve the module. If one of the measurements is good, the module is identified as non-problematic. The data service system may also include a test target coupled to a networking module of the data service system to allow service test signals to be measured through the network module.

The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism

Abstract: We show that cytochrome P450scc (CYP11A1) in either a reconstituted system or in isolated adrenal mitochondria can metabolize vitamin D3. The major products of the reaction with reconstituted enzyme were 20-hydroxycholecalciferol and 20,22-dihydroxycholecalciferol, with yields of 16 and 4%, respectively, of the original vitamin D3 substrate. Trihydroxycholecalciferol was a minor product, likely arising from further metabolism of dihydroxycholecalciferol. Based on NMR analysis and known properties of P450scc we propose that hydroxylation of vitamin D3 by P450scc occurs sequentially and stereospecifically with initial formation of 20(S)-hydroxyvitamin D3. P450scc did not metabolize 25-hydroxyvitamin D3, indicating that modification of C25 protected it against P450scc action. Adrenal mitochondria also metabolized vitamin D3 yielding 10 hydroxyderivatives, with UV spectra typical of vitamin D triene chromophores. Aminogluthimide inhibition showed that the three major metabolites, but not the others, resulted from P450scc action. It therefore appears that non-P450scc enzymes present in the adrenal cortex to some extent contribute to metabolism of vitamin D3. We conclude that purified P450scc in a reconstituted system or P450scc in adrenal mitochondria can add one hydroxyl group to vitamin D3 with subsequent hydroxylation being observed for reconstituted enzyme but not for adrenal mitochondria. Additional vitamin D3 metabolites arise from the action of other enzymes in adrenal mitochondria. These findings appear to define novel metabolic pathways involving vitamin D3 that remain to be characterized.

mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities

Abstract: As part of the Spotlight on Molecular Profiling series, we present here new profiling studies of mRNA and microRNA expression for the 60 cell lines of the National Cancer Institute (NCI) Developmental Therapeutics program (DTP) drug screen (NCI-60) using the 41,000-probe Agilent Whole Human Genome Oligo Microarray and the 15,000-feature Agilent Human microRNA Microarray V2. The expression levels of approximately 21,000 genes and 723 human microRNAs were measured. These profiling studies include quadruplicate technical replicates for six and eight cell lines for mRNA and microRNA, respectively, and duplicates for the remaining cell lines. The resulting data sets are freely available and searchable online in our CellMiner database. The result indicates high reproducibility for both platforms and an essential biological similarity across the various cell types. The mRNA and microRNA expression levels were integrated with our previously published 1,429-compound database of anticancer activity obtained from the NCI DTP drug screen. Large blocks of both mRNAs and microRNAs were identified with predominately unidirectional correlations to approximately 1,300 drugs, including 121 drugs with known mechanisms of action. The data sets presented here will facilitate the identification of groups of mRNAs, microRNAs, and drugs that potentially affect and interact with one another.

A 20 GS/s 8 b ADC with a 1 MB memory in 0.18 /spl mu/m CMOS

Abstract: A 20 GS/s 8-bit ADC achieves a bandwidth of 6 GHz in 0.18 /spl mu/m CMOS. The implementation uses 80 time-interleaved current-mode pipeline sub-ADCs and stores data at 20 GB/s into a 1 MB on-chip memory. The ADC is packaged with a BiCMOS input buffer chip in a 438-ball BGA, and total power consumption is 10 W.